TSE:IMV

IMV Competitors

C$3.39
+0.05 (+1.50 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
C$3.30
Now: C$3.39
C$3.42
50-Day Range
C$3.34
MA: C$3.98
C$4.84
52-Week Range
C$2.48
Now: C$3.39
C$9.25
Volume46,584 shs
Average Volume157,600 shs
Market CapitalizationC$229.54 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

IMV (TSE:IMV) Vs. BU, APS, BLU, TH, NRI, and PLI

Should you be buying IMV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to IMV, including Burcon NutraScience (BU), Aptose Biosciences (APS), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

IMV (TSE:IMV) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Profitability

This table compares IMV and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMVN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for IMV and Burcon NutraScience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV04002.00
Burcon NutraScience00103.00

IMV presently has a consensus target price of C$5.08, suggesting a potential upside of 49.95%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 1.19%. Given IMV's higher probable upside, research analysts plainly believe IMV is more favorable than Burcon NutraScience.

Valuation and Earnings

This table compares IMV and Burcon NutraScience's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87
Burcon NutraScienceC$12,045.0044,992.20C$107,101.00C$0.005,060.00

Burcon NutraScience has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats IMV on 6 of the 8 factors compared between the two stocks.

IMV (TSE:IMV) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares IMV and Aptose Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87
Aptose BiosciencesN/AN/AN/AC($0.84)-7.20

Aptose Biosciences has lower revenue, but higher earnings than IMV. Aptose Biosciences is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for IMV and Aptose Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV04002.00
Aptose Biosciences00203.00

IMV currently has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Aptose Biosciences has a consensus target price of C$12.00, indicating a potential upside of 97.37%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than IMV.

Profitability

This table compares IMV and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMVN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

BELLUS Health (TSE:BLU) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares BELLUS Health and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
IMVN/AN/AN/A

Valuation & Earnings

This table compares BELLUS Health and IMV's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$15,000.0029,298.04C$-52,720,801.00C($0.67)-8.34
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87

IMV has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BELLUS Health and IMV, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
IMV04002.00

IMV has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than BELLUS Health.

Summary

IMV beats BELLUS Health on 5 of the 8 factors compared between the two stocks.

Theratechnologies (TSE:TH) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Theratechnologies and IMV, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
IMV04002.00

Theratechnologies currently has a consensus price target of C$3.75, indicating a potential downside of 16.67%. IMV has a consensus price target of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher possible upside, analysts plainly believe IMV is more favorable than Theratechnologies.

Valuation and Earnings

This table compares Theratechnologies and IMV's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$65.76 million6.47C$-35,948,380.00C($0.38)-11.84
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87

Theratechnologies has higher revenue and earnings than IMV. Theratechnologies is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
IMVN/AN/AN/A

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
IMV04002.00

IMV has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher probable upside, analysts plainly believe IMV is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
IMVN/AN/AN/A

Valuation and Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.26C$-6,980,844.00C($0.61)-57.38
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than IMV. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

ProMetic Life Sciences (TSE:PLI) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Profitability

This table compares ProMetic Life Sciences and IMV's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
IMVN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for ProMetic Life Sciences and IMV, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
IMV04002.00

IMV has a consensus target price of C$5.08, suggesting a potential upside of 49.95%.

Earnings and Valuation

This table compares ProMetic Life Sciences and IMV's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
IMVC$3,000.0076,513.43C$-39,136,958.00C($0.58)-5.87

IMV has lower revenue, but higher earnings than ProMetic Life Sciences. IMV is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.


IMV Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BU
Burcon NutraScience
1.2$5.06+0.2%C$541.93 millionC$12,045.005,060.00
APS
Aptose Biosciences
1.3$6.08+4.8%C$540.42 millionN/A-7.20
BLU
BELLUS Health
0.5$5.61+3.2%C$439.47 millionC$15,000.00-8.34
Theratechnologies logo
TH
Theratechnologies
0.7$4.50+0.2%C$425.70 millionC$65.76 million-11.84Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.18+0.5%C$400.57 millionC$76.09 million-57.38
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
MDNA
Medicenna Therapeutics
0.5$4.82+0.6%C$254.99 millionN/A-15.60
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.47+8.2%C$243.28 millionC$52.78 million-1.09Gap Up
RVX
Resverlogix
0.7$0.89+2.2%C$208.25 millionN/A63.57Upcoming Earnings
News Coverage
FRX
Fennec Pharmaceuticals
0.5$7.85+2.9%C$204.12 millionC$170,000.00-8.21Gap Up
ONC
Oncolytics Biotech
1.2$3.80+4.7%C$200.52 millionN/A-6.79
ATE
Antibe Therapeutics
1.3$4.27+6.3%C$194.32 millionC$9.33 million-5.43Gap Down
HBP
Helix BioPharma
0.5$0.88+3.4%C$124.20 millionN/A-16.00
IPA
ImmunoPrecise Antibodies
0.4$11.63+5.0%C$123.03 millionC$17.18 million-54.35
ACST
Acasti Pharma
0.8$0.53+3.8%C$88.79 millionC$81,000.0015.59
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60+1.7%C$65.67 millionC$11.64 million-11.76
SBM
Sirona Biochem
0.5$0.36+4.2%C$58.80 millionC$123,870.00-27.69
PMN
ProMIS Neurosciences
0.5$0.18+0.0%C$55.07 millionC$1,787.00-9.00Gap Down
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36
IGX
IntelGenx Technologies
0.9$0.53+1.9%C$30.87 millionC$1.54 million-6.54
QPT
Quest PharmaTech
0.8$0.11+4.8%C$21.76 millionC$38,871.000.16High Trading Volume
Gap Up
CZO
Ceapro
0.7$0.72+2.8%C$21.65 millionC$16.14 million21.82
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57High Trading Volume
GSD
Devonian Health Group
0.5$0.28+7.1%C$13.96 millionC$1.59 million-5.83Gap Down
PAS
Pascal Biosciences
0.6$0.08+6.3%C$12.70 millionN/A-3.64Gap Up
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.33+3.0%C$10.16 millionC$4.12 million30.00Gap Down
HEM
Hemostemix
0.6$0.34+1.5%C$9.07 millionN/A-2.02Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.69+3.5%C$4.48 millionN/A-1.19
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3N/AN/AC$0.00C$267.59 million51.46
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.